Tempus Next Structural Heart capabilities include screening for appropriate care across aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonary regurgitation. Tempus Next delivers guidelines driven notifications to help providers close care gaps in these populations.

Within cardiomyopathies, Tempus Next screening protocols address care across non-ischemic dilated cardiomyopathy and cardiac oncologic disease. Our mission is to shorten the time to referral for consideration of advanced heart failure treatment options like left ventricular assist devices or heart transplants. We also aim to enable clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists based on guidelines.

Tempus Next electrophysiology capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States; however, prevention is challenging due to difficulty identifying at-risk patients.² Less than 10% of patients who meet the AHA/ACC/HRS guidelines criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device, with women more likely to be undertreated.³ Tempus Next continuously monitors patient data to find at-risk patients, and alerts the patient’s care team of any guidelines based follow-up or disease progression.

Tempus Next screens for an array of additional conditions including congestive heart failure and ischemic heart diseases. Our program monitors length of time and patient adherence to Guideline Directed Medical Therapy, as well as key markers including ejection fraction during this period to determine the potential need for referral to a heart clinic based on guidelines. Studies have shown that patients not optimized on Guideline Directed Medical Therapy are 26% more likely to have higher annualized healthcare utilization and emergency department visits.⁴

Tempus is sponsoring a multi-site study of an investigational AI algorithm that analyzes the results of a 12-lead electrocardiogram (ECG) to find patients at increased risk of having undetected pulmonary hypertension (PH). Clinicians will evaluate the AI’s ability to detect patients at risk of undiagnosed PH, and will track clinical outcomes of patients who are identified for further evaluation. The study will leverage Tempus Next, our care pathway intelligence solution, to facilitate the PH algorithm’s investigational use at participating institutions.